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Whole exome sequencing identifies causative
mutations in the majority of consanguineous or
familial cases with childhood-onset increased renal
echogenicity
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Chronically increased echogenicity on renal ultrasound is a
sensitive early finding of chronic kidney disease that can be
detected before manifestationQ4 of other symptoms. Increased
echogenicity, however, is not specific for a certain etiology of
chronic kidney disease. Here, we performed whole exome
sequencing in 79 consanguineous or familial cases of
suspected nephronophthisis in order to determine the
underlying molecular disease cause. In 50 cases, there was a
causative mutation in a known monogenic disease gene. In
32 of these cases whole exome sequencing confirmed the
diagnosis of a nephronophthisis-related ciliopathy. In 8 cases
it revealed the diagnosis of a renal tubulopathy. The
remaining 10 cases were identified as Alport syndrome (4),
autosomal-recessive polycystic kidney disease (2), congenital
anomalies of the kidney and urinary tract (3), and APECED
syndrome (1). In 5 families, in whom mutations in known
monogenic genes were excluded, we applied homozygosity
mapping for variant filtering and identified 5 novel candidate
genes (RBM48, FAM186B, PIAS1, INCENP, and RCOR1) for renal
ciliopathies. Thus, whole exome sequencing allows the
detection of the causative mutation in 2/3 of affected
individuals, thereby presenting the etiologic diagnosis, and
allows identification of novel candidate genes.
Kidney International (2015) 00, 1–8. doi:10.1038/ki.2015.317
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Renal ultrasound imaging (RUS) represents a simple and
broadly accessible tool for the noninvasive early diagnosis of
chronic kidney disease (CKD) in children and young adults.
Often abnormal findings on RUS are detectable years before
the kidney function deteriorates and before other symptoms
develop. A typical abnormal finding in early stages of CKD is
chronically increased echogenicity on RUS. It is frequently
accompanied by loss of cortico-medullary differentiation and
renal cysts. Increased echogenicity is easily detected as a
degree of echogenicity that is equal to or more pronounced
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than the echogenicity of the liver. Unfortunately, chronically
increased echogenicity is not specific to certain types of
kidney disease.1–3 Particularly in early stages, in which other
symptoms are not yet present, a correct diagnosis can be
challenging. In these cases, whole-exome sequencing (WES)
provides a novel means of establishing an etiologic diagnosis.
By revealing the causative monogenic mutation, it provides
affected individuals and their families with an unequivocal,
early diagnosis.1 As a result, a targeted therapeutic regimen
can be initiated early if available.
Chronically increased echogenicity on RUS is often found
in the early stages of nephronophthisis-related ciliopathies
(NPHP-RCs). NPHP-RCs represent a group of cystic and
fibrotic kidney diseases with an autosomal recessive mode of
inheritance that typically progress to end-stage renal failure
within the first three decades of life.4,5 Nephronophthisis can
present as isolated renal disease (MIM #613550) or together
with extrarenal symptoms such as retinal degeneration
(Senior Loken syndrome MIM #266900), cerebellar vermis
hypoplasia (Joubert syndrome MIM #213300), and hepatic
fibrosis. The renal manifestation ranges from severe, early
onset cystic kidney disease6 to slowly progressive, fibrotic
remodeling of the kidney with CKD starting in adolescence.7
Interestingly, the genotype–phenotype correlation in NPHP-
RC is dependent on the gene and the specific mutation
involved, which can both give rise to a broad phenotypic
disease spectrum. NPHP-RCs are a very heterogeneous
disease group, as by now mutations in more than 90 genes
have been identified as causative for renal ciliopathies in
humans.4 Mutations in some of these genes are very rare,
accounting for only two8 or three9 families worldwide. WES
with direct inspection of the coding regions of these genes
therefore represents the most rational and currently, most
cost-effective approach for mutation analysis in these
patients.1,10–12 So far, no more than 13 ciliopathy genes have
been systematically studied in a larger patient cohort.13,14
Here, we performed WES combined with homozygosity
mapping in an international cohort of 79 families with pediatric
onset of CKD and suspected nephronophthisis based on renal
ultrasound presentation with chronically increased echogenicity,
loss of cortico-medullary differentiation, and/ or ⩾ 2 cysts. All
individuals were born of consanguineous union, or represented
familial cases of CKD, and were therefore at high risk for
recessive, monogenic diseases. In summary, we were able to
identify a mutation in a known monogenic disease gene in 50
families (63.3%). In 32 of these families (64%), WES identified
mutations in NPHP-RC genes as the molecular disease cause
and confirmed the suspected clinical diagnosis. However, in 18
families (36%), we discovered a molecular diagnosis of a
monogenic kidney disease that was not NPHP-RC, specifically
renal tubulopathies (n= 8, 16%), Alport syndrome (n= 4, 8%),
congenital anomalies of the kidney and urinary tract (CAKUT)
(n= 3, 6%), autosomal recessive polycystic kidney disease
(ARPKD) (n= 2, 4%), and autoimmune nephropathy
(APECED (autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy) syndrome) (n= 1, 2%). In five con-
sanguineous families, in whom we excluded mutations in
known monogenic disease genes, we identified five novel
candidate genes for NPHP-RC (RBM48, FAM168B, PIAS1,
INCENP, and RCOR1).
RESULTS
WES identifies the molecular disease cause in 63% of cases
We performed WES in 79 families with suspected NPHP-RC
based on renal ultrasound criteria (chronically increased echo-
genicity, loss of cortico-medullary differentiation, and/or ⩾2
renal cysts). In 50/79 families (63.3%), we identified a mutation
in a gene that is known to cause monogenic renal disease when
mutated (Figure 1a, Supplementary Tables S1 and S2 online).
NPHP-RCs account for 64% of molecularly diagnosed
individuals
Thirty-two of the 50 families with established molecular
diagnosis after WES (64.0%) harbored a mutation in a known
NPHP-RC gene (Figure 1b). Of the 90 genes that are known
to cause renal ciliopathies when mutated, which were syste-
matically analyzed in this study, mutations in 18 genes contri-
buted to this result. Mutations in the genes NPHP3, NPHP4,
and NPHP5 accounted for the majority of NPHP-RC cases
(Table 1, Supplementary Tables S1 and S2 online). In
addition to mutations in NPHP-RC genes, we detected
causative mutations in monogenic genes of renal tubulopa-
thies (8/50), Alport syndrome (4/50), CAKUT (3/50), and
ARPKD (2/50). Furthermore, we established the molecular
diagnosis of APECED in one previously undiagnosed
individual (Figure 1b, Table 1, Supplementary Tables S1
and S2 online). In 10 individuals, the molecular diagnosis
after WES was different from the previous clinical diagnosis.
In particular, in one case of previously undiagnosed nephro-
pathic cystinosis the molecular finding changed the thera-
peutic regimen (Supplementary Tables S1 and S2 online).
Mutations in more than one recessive disease gene can be
present in consanguineous families
In one example of a highly inbred family (412Mb of
cumulative homozygosity), we identified homozygous muta-
tions in seven known monogenic disease genes. Four of them
are known to cause diseases with renal involvement (Supple-
mentary Table S3 online). The affected child showed a
complex phenotype suggestive of a renal ciliopathy, including
Caroli’s disease with massive cystic dilation of intrahepatic
bile ducts, CKD that progressed to end-stage renal failure
within the third year of life, post-axial polydactyly, nystagmus,
and red cone dystrophy. In addition to chronically increased
echogenicity as the classical symptom of NPHP-RC, the child
showed congenital hydronephrosis due to uretero-pelvic
junction obstruction that required corrective surgery, as well
as renal tubular acidosis type 4. (Supplementary Table S3
online). An older brother, from whom no DNA sample was
available for mutation analysis, deceased at 15 months of age
due to end-stage renal and liver disease. In addition, he
showed post-axial polydactyly and blindness at 5 months of
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age due to progressive retinal dystrophy. A younger brother
presented with Caroli’s disease and retinitis pigmentosa.
Interestingly, no polydactyly was present, and the renal
function was preserved at 3 years of age. The right kidney
showed mild pelvicalyceal dilation.
The percentage of molecularly solved cases in consanguineous
families and familial cases of suspected NPHP-RC is comparable
(~63%). When performing WES in 79 families with
suspected nephronophthisis based on RUS with childhood-
onset chronically increased renal echogenicity and/or ⩾ 2
renal cysts, we detected a causative mutation in a known
monogenic disease gene in 38 of 60 consanguineous families
(63.3%) (Figure 2). As postulated15,16 in the vast majority of
consanguineous families, the causative mutation was present
in the homozygous state (37 of 38 families (97.4%))
(Figure 2). The only exception was a family in whom we
identified a single heterozygous mutation in the dominant
gene HNF1ß as causative. In 12 of 19 non-consanguineous
families with 2 or more affected children (63.2%), we
identified a causative monogenic mutation, showing a
comparable percentage of molecularly solved cases in both
cohorts. However, as expected in non-consanguineous
families,16 only in 3 of 12 families (25.0%) the disease-
causing mutation was present in the homozygous state. The
remaining 9 of 12 families (75.0%) harbored two compound
heterozygous disease-causing mutations (Figure 2).
Identification of five novel candidate genes for NPHP-RC
By applying homozygous peak regions as a filter for WES data,
we identified five novel candidate genes for monogenic,
recessive NPHP-RC (Table 2). In these five consanguineous
families, we had excluded mutations in known monogenic
disease genes with renal phenotypes through evaluation and
direct inspection of the WES data. The five novel candidate
genes (RBM48, FAM168B, PIAS1, INCENP, and RCOR)
represented the most deleterious alleles within the homozygous
regions (Supplementary Figure S2 online) after variant filtering
as outlined in Supplementary Figure S1 online. In the example
of family A2621 with 181Mb of cumulative homozygosity
(Supplementary Table S4 online), we started with 482,406
variants from normal reference sequence. Excluding common
variants (minor allele frequency 41% in healthy control
cohorts), synonymous variants, and heterozygous variants
reduced the number to 1699. Considering only variants that
were positioned within homozygous peak regions reduced
the number of remaining variants by 11-fold to 156.
Exclusion of artifacts by direct inspection of the sequence
alignment left us with three potentially disease-causing
variants in this family (Supplementary Table S4 online).
Subsequently, these these variants were ranked based on
their predicted likelihood to be deleterious for the function
of the encoded protein following the criteria as outlined in
Supplementary Figure S1 online. At the end of the filtering
process, the gene INCENP (inner centromere protein)
represented the strongest remaining variant in this family.
All mutations in novel candidate genes were confirmed by
Sanger sequencing in original patient DNA and segregated
with the affected status.
Twenty-four families (30.4%) remained without a mole-
cular diagnosis after WES. In these families, no convincing
32
(64%)
8 (16%)
4 (8%)
2 (4%)
3 (6%) 1 (2%)
Nephronophthisis-related ciliopathies
Renal tubulopathies
Alport syndrome
ARPKD
CAKUT
APECED (autoimmune nephropathy)
50 (63.3%)5 (6.3%)
24 (30.4%)
Causative mutation in a known monogenic gene
Mutation in a novel candidate gene for NPHP-RC
Without molecular diagnosis after WES
a bn = 79 n = 50
Figure 1 |Relative number of cases molecularly diagnosed by whole-exome sequencing (WES) in 79 families with childhood-onset
chronically increased echogenicity or ⩾ 2 cysts on renal ultrasound. (a) We performed WES in 79 consanguineous or sibling cases with
increased echogenicity and/or ⩾ 2 cysts on renal ultrasound. In 50 families (63.3%), we identified a mutation in a known monogenic disease
gene as causative. In 5 families (6.3%), we identified a mutation in a novel candidate gene for NPHP-RC, and 24 families (30.4%) remained
without a molecular diagnosis after WES. (b) Fractional contribution of different disease entities to the molecular diagnosis of 50 families in
whom a causative mutation in a known monogenic disease gene was detected (see Table 1 for the underlying monogenic causes in each
disease group).
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biallelic variants in known monogenic genes or candidate
genes were identified that segregated with the affected
status.
DISCUSSION
We performed WES combined with homozygosity mapping
in 79 consanguineous or familial cases of childhood-onset
chronically increased renal echogenicity or the presence of ⩾ 2
cysts on renal ultrasound. On the basis of renal ultrasound
presentation, clinical presentation with childhood-onset of
disease, and if available renal histology, an NPHP-RC was
suspected as the primary disease cause. We show that, in this
patient cohort, WES allows detecting the specific causative
mutation in about two-third of affected individuals, thereby
presenting the etiologic diagnosis. In addition, we identified
five potential novel renal ciliopathy genes in consanguineous
families in whom mutations in 90 known monogenic
NPHP-RC genes had been excluded.
Chronically increased echogenicity on renal ultrasound
represents a sensitive diagnostic criterion for early stages of
CKD in children and young adults. Typically, this results in
the suspected diagnosis of nephronophthisis or related
ciliopathies. However, we and others1–3 have shown that
other kidney diseases can phenocopy the presentation of
NPHP-RC on renal ultrasound. Here, we study 79
consanguineous or familial cases with suspected NPHP-RC
based on renal ultrasound presentation with childhood-onset
increased renal echogenicity and/or more than one cyst, and
perform WES in order to determine the percentage in which
NPHP-RC and various other monogenic, recessive kidney
diseases contribute to this phenotypic spectrum (Figure 2). As
a second aspect, we aimed to systematically examine all 90
genes that are known monogenic, recessive causes of
NPHP-RC or other CKD that can phenocopy the presenta-
tion of NPHP-RC in a large cohort of affected individuals. So
far, this has not been done for more than 13 renal ciliopathy
genes13,14 at a time. As we identified the disease-causing
mutation in ~ 2/3 (50/79) of individuals with increased
echogenicity on RUS, our data show that WES is an efficient
tool for molecular diagnostics in this patient cohort. WES
Table 1 |Diagnostic groups and distribution among specific genes with causative recessive mutations in 50 families with
increased echogenicity and/or ⩾2 cysts on renal ultrasound in whom the disease-causing mutation was detected by WES
Disease group Patients within the disease group Gene with causative mutation (disease, OMIM#a)
NPHP-RC 32/50 (64.0%)
2/50 (4.0%) NPHP1 (nephronophthisis type, juvenile, #256100)
3/50 (6.0%) NPHP3 (nephronophthisis type 3, #604387 )
5/50 (10 %) NPHP4 (nephronophthisis type 4, #606966)
3/50 (6.0%) IQCB1 (Senior-Loken syndrome type 5, #609254)
1/50 (2.0%) CEP290 (Senior-Loken syndrome 6, #610189)
2/50 (4.0%) SDCCAG8 (Senior-Loken syndrome type 7, #613615)
1/50 (2.0%) TMEM67 (nephronophthisis 11, #613550)
2/50 (4.0%) TTC21B (nephronophthisis 12, #613820)
2/50 (4.0%) WDR19 (nephronophthisis 13, #614377)
3/50 (6.0%) ANKS6 (nephronophthisis 16, #615382)
1/50 (2.0%) TMEM138 (Joubert syndrome 16, #614465)
1/50 (2.0%) TMEM231 (Joubert syndrome 20, #614970)
1/50 (2.0%) ARL6 (Bardet-Biedl syndrome 3, #600151)
1/50 (2.0%) BBS4 (Bardet-Biedl syndrome 4, #615982)
1/50 (2.0%) MKKS (Bardet-Biedl syndrome 6, #605231)
1/50 (2.0%) BBS12 (Bardet-Biedl syndrome 12, #615989)
1/50 (2.0%) DYNC2H1 (short-rib thoracic dysplasia 3, #613091)
1/50 (2.0%) IFT43 (cranioectodermal dysplasia 3, #614099)
Renal tubulopathies 8/50 (16.0%)
3/50 (6.0%) CLDN16 (hypomagnesemia 3, renal, #248250)
2/50 (4.0%) CLCNKB (Bartter syndrome, type 3, #607364)
1/50 (2.0%) ATP6V0A4 (renal tubular acidosis, distal, #602722)
1/50 (2.0%) BCS1L (mitochondrial complex III deficiency, #124000)
1/50 (2.0%) CTNS (cystinosis, nephropathic, #219800)
Alport syndrome 4/50 (8.0%)
2/50 (4.0%) COL4A3 (Alport syndrome, #203780)
1/50 (2.0%) COL4A4 (Alport syndrome, #203780)
1/50 (2.0%) COL4A5 (Alport syndrome, #301050)
CAKUT 3/50 (6.0%)
2/50 (4.0%) HNF1b (renal cysts and diabetes syndrome, #137920)
1/50 (2.0%) FREM2 (Fraser syndrome, #219000 )
Autosomal recessive polycystic kidney disease
2/50 (4.0%) PKHD1 (polycystic kidney and hepatic disease, #263200)
APECED 1/50 (2.0%) AIRE (autoimmune polyendocrinopathy syndrome type I, #240300)
Abbreviations: APECED, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy; CAKUT, congenital anomalies of the kidney and urinary tract; NPHP-RC,
nephronophthisis-related ciliopathies.
aOnline Mendelian Inheritance in Man (OMIM), http://www.omim.org.
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provides affected individuals and their families with an
unequivocal diagnosis that avoids unnecessary diagnostic and
therapeutic interventions. WES is a noninvasive diagnostic
tool with little risk, and, recently, the cost has dropped to a
level that makes it accessible to a broader group of affected
individuals in a clinical rather than a research setting.
Considering the genetic heterogeneity of NPHP-RC, WES is
the only available technique that can reliably establish the
correct molecular diagnosis. The use of targeted sequencing
panels as utilized for other disease entities in clinical genetics
is technically not feasible and/or not economical for such
a large number of potentially causative genes. However,
WES yields a large number of variants from normal reference
sequence, most of which are functionally irrelevant.
Therefore, an efficient strategy for variant filtering is
indispensable for the work with WES data. In addition,
variant calling should follow an indication-driven strategy:
After thorough clinical evaluation, a subset of potentially
causative genes should be defined prior to WES, and the
evaluation should primarily focus on variants in these
genes. For example, in a patient with increased echogenicity
and/or ⩾ 2 cysts on renal ultrasound, primarily variants in
the ~ 90 monogenic causes of renal ciliopathies, and genes
that can phenocopy NPHP-RC, should be taken into
consideration.
In our cohort, WES molecularly confirmed the clinically
suspected diagnosis of NPHP-RC in 64% of cases. However,
18/50 individuals (36%) harbored a mutation in a gene that
Suspected nephronophthisis based on
childhood-onset chronically increased
renal echogenicity and/or2 cysts
(79 families)
Parents are
consanguineous
(60 families, 75.9%)
Causative monogenic
mutation detected
(38 families, 63.3%)
Homozygous disease
causing mutation
(3 families, 25.0%)
Compound
heterozygous disease
causing mutation
(9 families, 75.0%)
Homozygous disease
causing mutation
(37 families, 97.4%)a
Familial cases with 2 or
more affected children
(19 families, 24.1%)
No causative
monogenic mutation
detected
(22 families, 36.7%)
Causative monogenic
mutation detected
(12 families, 63.2%)
No causative
monogenic mutation
detected
(7 families, 36.8%)
Figure 2 |Algorithm for molecular diagnostics in consanguineous or familial cases of suspected nephronophthisis based on renal
ultrasound presentation. Of the 79 families with childhood-onset increased renal echogenicity and/or ⩾ 2 cysts on renal ultrasound
imaging, 60 individuals were born of consanguineous unions and 19 families were non-consanguineous with two or more affected children.
In 63.3% of consanguineous families, we identified a mutation in a known monogenic disease gene as causative. The majority of these
mutations were, as postulated, present in the homozygous state. In 63.2% of familial cases, we identified a causative mutation in a recessive,
monogenic disease gene. Three-fourths of these mutations were compound heterozygous. aIn one consanguineous family, a single
heterozygous mutation in the dominant gene HNF1ß was identified as the molecular disease cause.
Table 2 |Novel candidate genes for NPHP-RC identified in five families with increased echogenicity and/or ⩾ 2 cysts on renal
ultrasound in whom a causative mutation in a known monogenic disease gene was excluded
Family Gene Zygosity Accession # c.Position p.Position
Continuosly
conserved to
Polyphen-2/
MutTast/SIFT ExAc EVSa
Clinical
diagnosis
A2621 INCENP Hom NM_020238.2 c.2403G4C p.Gln801His Danio rerio 0.96/DC/del 0/337/120826 0/32/4267 NPHP
A1833 RBM48 Hom NM_032120.2 c.835A4G p.Thr279Ala Ciona intestinalis 0.71/DC/del 0/5/120562 Not present NPHP+JATD
A2275 FAM186B Hom NM_032130.2 c.506-2A4G Obligatory splice site mutation 0/1/111410 Not present NPHP
A2287 PIAS 1 Hom NM_016166.1 c.317C4T p.Ser106Leu Danio rerio 0.77/DC/del 0/3/120766 Not present NPHP
A1239 RCOR1 Hom NM_015156.2 c.437-3C4T Splice site mutation 0/3/121306 not present JBTS
Abbreviations: DC, disease causing (MutationTaster); del, deleterious (SIFT); EVS, exome variant server; ExAc, Exome Aggregation Consortium; JATD, Jeune asphyxiating
thoracic dystrophy; JBTS, Joubert syndrome; MutTast, MutationTaster; NPHP, nephronophthisis; SIFT, sorting intolerant from tolerant (SIFT).
Each candidate gene represents the most deleterious mutation within the homozygous peak regions of the respective family.
agenotypes in European Americans.
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causes a monogenic kidney disease different from NPHP-RC.
As already described in a smaller cohort,1 the majority of
these cases (8/18) were diagnosed as renal tubulopathies.
In addition, we identified four individuals with Alport
syndrome, three individuals with mutations in CAKUT genes,
two individuals with ARPKD, and one individual with
autoimmune nephropathy in the context of APECED
syndrome. In 10 of these 18 cases, the molecular diagnosis
differed from the initial clinical diagnosis. We therefore
suggest that WES helps distinguish between NPHP-RC and
other kidney diseases that phenocopy the presentation of
NPHP-RC on renal ultrasound. This can be particularly
advantageous in very early stages of disease progression in
which additional characteristic symptoms might not yet
be present, as well as for very rare genetic syndromes.
This observation underlines an additional benefit of WES:
The genetic diagnostic is not restricted to a limited subset of
monogenic diseases that were already suspected based on the
clinical presentation, but a broader spectrum of monogenic
causes can be taken into consideration. In addition, the very
high rate of detecting a causative mutation in genes that are
known to be mutated in renal disorders with increased
echogenicity confirms that increased renal echogenicity,
even if performed in numerous centers worldwide, is a
reproducible and reliable criterion for noninvasive
diagnostic in pediatric kidney disease. Interestingly, the
percentage of molecularly diagnosed individuals was not
considerably different in consanguineous families as
compared with outbred sibling cases. We therefore suggest
that the relevance of our findings reaches beyond
consanguineous cases.
As we and others have shown10,12,17 combining WES and
homozygosity mapping in consanguineous families represents
a powerful tool for the identification of novel human disease
genes. We applied this technique in five families in whom
mutations in known human disease genes had been excluded,
and we identified RBM48, FAM168B, PIAS1, INCENP, and
RCOR1 as novel candidate genes for renal ciliopathies. So far,
mutation analysis has not yielded additional families with
mutations in these genes. However, this rarity is not
unexpected as for the majority of recently identified NPHP-
RC genes less than 10 families with mutations have been
described worldwide.9–12,18–20 At this point, additional
functional evidence to proof the pathogenicity of these
mutations is lacking. Further genetic and experimental
evidence in the future will help determine whether mutations
in these newly identified candidate genes are indeed disease
causing in humans with renal ciliopathies.
Twenty-four of 79 families in our cohort (30.4%)
remained without a molecular diagnosis after WES. This is
not unexpected as in recessive monogenic diseases only about
85% of all causative mutations are located within the coding
sequence or the adjacent splice sites.21,22 The remaining
15%, however, are complex deletion–insertion variants,
copy-number variants, or reside within a promotor and
other intronic region. As none of these variants can be
detected by WES, this technical limitation explains why
some cases cannot be solved by WES. Furthermore, WES
might miss a subset of causative variants due to low coverage
in the respective target region. Considering the fact that about
20% of all individuals with NPHP-RC harbor a homozygous
deletion in the NPHP1 gene, the percentage of solved
cases in this study had been even higher than the reported
63% if these cases were included. As it has been postulated
that only 85% of recessive mutations can be
technically detected with currently available techniques,22
we show that in the targeted patient cohort virtually all cases
with detectable recessive mutations are molecularly solved
after WES.
We here present WES as a rapid and reliable tool for
molecular diagnostics in consanguineous individuals or
familial cases with clinically suspected NPHP-RC based on
renal ultrasound that allows establishing an etiologic diagnosis
in ~ 2/3 of affected individuals. This represents a major
advance in a diagnostic finding that is frequently interpreted
as ‘medical renal disease’ rather than leading to an etiologic
diagnosis.
MATERIALS AND METHODS
Human subjects
The study was approved by the institutional review board of the
University of Michigan and Boston Children’s Hospital. After
obtaining informed consent, clinical data, and pedigree information,
DNA samples were collected from individuals with suspected
nephronophthisis based on clinical findings, renal ultrasound
criteria, and, if present, renal histology. Subjects were either of
consanguineous families or of sibling cases with multiple affected
children in one family. A total of 107 individuals from 82 families
were included in the study. Four individuals (from 3 families) were
excluded for technical reasons, leading to a final cohort of 103
individuals from 79 families. Sixty families were consanguineous
singlets, and 19 families were non-consanguineous familial cases
with more than one affected child (16 families with 2 affected
children, 2 families with 3 affected children, and 1 family with 5
affected children). In all families, a homozygous deletion in the
NPHP1 gene had been excluded prior to study inclusion. This was
necessary as homozygous deletions in the NPHP1 gene represent
the most frequently observed mutation in individuals with
nephronophthisis but cannot be detected by WES.
Linkage analysis
For genome-wide homozygosity mapping, the GeneChip Human
Mapping 250k Sty Array from Affymetrix Q5was used. Nonparametric
LOD scores were calculated using a modified version of the program
GENEHUNTER2.123,24 through stepwise use of a sliding window
with sets of 110 single-nucleotide polymorphisms and the program
ALLEGRO25 in order to identify regions of homozygosity as
described,15,26 using a disease allele frequency of 0.0001 and
Caucasian marker allele frequencies. The genetic mapping was based
on multipoint analysis. A nonparametric LOD score of 2 was applied
as the threshold for relevant homozygous peak regions and a
nonparametric LOD cutoff of 0.5 as threshold for linkage in
sibling cases.
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Whole human exome capture, next gen sequencing, sequence
alignment, and variant calling
Genomic DNA was isolated from blood lymphocytes and subjected
to whole-exome capture using a customized Agilent SureSelect All
Exome Kit v2.0 (Agilent Technologies, Santa Clara, CA) according
to the manufacturer’s protocol. The library was sequenced on an
Illumina HighSeq sequencing platform. Image analysis and base
calling were generated by the Illumina pipeline using default
parameters. Sequence reads were mapped to the human reference
genome assembly (NCBI build 3/hg19) using CLC Genomics
Workbench (version 6.5.2) software (CLC bio, Aarhus, Denmark).
In consanguineous cases, only variants with a common allele
frequency of more than 80% were called for further evaluation in
order to identify homozygous variants. Trimmed sequence reads
were mapped to the human reference genome (hg19) using the Map
Reads to Reference program with the following settings: mismatch
cost= 2, insertion cost= 3, deletion cost = 3, length fraction= 0.5,
similarity fraction= 0.9, and map to nonspecific reads= ‘randomly’.
The nonspecific reads were then ignored for count and coverage. All
variants with a minimum coverage of 2 were used. The variations in
the samples were called using probabilistic variant detection using
CLC bio. All the called variants were then annotated and evaluated
using mutation calling criteria as outlined in Supplementary Figure
S1 online.
Variant annotation and evaluation
After alignment to the human reference genome, variants were filtered
as previously described1,27 and as summarized in Supplementary
Figure S1 online. The ranking and calling of alleles as disease-causing
mutations followQ6 accepted standards in molecular diagnostics,28–31
and, with regard to the composition of our cohort, we applied criteria
that are even stricter than the ones typically used in the field. In the
first step, variants with minor allele frequencies 41% in the dbSNP
(version 135) or the 1000 genomes (1094 subjects of various
ethnicities; May, 2011 data release) databases were excluded. In the
second step, only homozygous and biallelic variants (in non-
consanguineous cases) were kept, whereas single heterozygous variants
were excluded from the further evaluation. Subsequently, in step 3,
synonymous variants and intronic variants that were not located
within splice site regions were excluded. In step 4, genetic mapping
data (homozygosity mapping in consanguineous families and linkage
analysis in sibling cases) were applied for variant filtering.15 In the final
step, remaining variants were ranked based on their probable impact
on the function of the encoded protein. We considered only mutations
as disease causing that fullfilled the following criteria: (a) protein-
truncating, or (b) previously reported as disease causing in individuals
with a similar phenotype (HGMD biobase), or (c) missense mutations
were only included if they affected highly conserved amino acid
residues (conserved in orthologs below vertebrate evolution) and were
not reported with a minor variant frequency 40.5% in healthy
control individuals, and were predicted to be deleterious for the
protein function (PolyPhen-2 score32 40.7). Variants that were
present in the homozygous state in any publicly available control
cohort were excluded. Mutation calling was performed by geneticists/
cell biologists, who had knowledge of the clinical phenotypes and
pedigree structure, as well as experience with homozygosity mapping
and exome evaluation. Remaining variants were confirmed in original
patient DNA by Sanger sequencing as previously described.33
Whenever parental DNA was available, segregation analysis was
performed.
In a second evaluation process, variants in all 90 genes that are
known monogenic, recessive causes of NPHP-RC or other CKD that
can phenocopy the presentation of NPHP-RC were systematically
evaluated.
WEB RESOURCES
UCSC Genome Browser, http://genome.ucsc.edu/cgi-bin/
hgGateway.
1000 Genomes Browser, http://browser.1000genomes.org;
Ensembl Genome Browser, http://www.ensembl.org;
Exome Variant Server, http://evs.gs.washington.edu/EVS;
Exome Aggregation Consortium, exac.broadinstitute.org;
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org;
Polyphen2, http://genetics.bwh.harvard.edu/pph2;
Sorting Intolerant From Tolerant (SIFT), http://sift.jcvi.org/
MutationTaster http://www.mutationtaster.org/
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families with increased echogenicity and/or ⩾ 2 cysts on RUS, in
whom a causative mutation in a known monogenic disease gene was
detected by WES.
Table S3. Mutations in 7 known monogenic disease genes in an
inbred family with three affected children.
Table S4. Variant filtering process in individual A2621 from a
consanguineous kindred (180.9 Mb of cumulative homozygosity)
using homozygous peak regions as candidate regions for the
identification of the causative recessive gene.
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